Publications (83) Paul Nguewa publications

2024

  1. Patología y diagnóstico I: Comunicaciones Orales 14

    ParaJournal: Revista de la Sociedad Española de Parasitología, Núm. 5, pp. 171-178

  2. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 4

  3. Structure and activity of amphiphilic PEO-PPO-based polymeric micelles and gels incorporating host–guest complexes of miltefosine as novel formulations for the treatment of leishmaniasis

    Journal of Molecular Liquids, Vol. 400

2023

  1. Advances in Biomedical Applications of Solution Blow Spinning

    International Journal of Molecular Sciences, Vol. 24, Núm. 19

  2. Ameliorating the antiparasitic activity of the multifaceted drug ivermectin through a polymer nanocapsule formulation

    International Journal of Pharmaceutics, Vol. 639

  3. BRCT Domains: Structure, Functions, and Implications in Disease—New Therapeutic Targets for Innovative Drug Discovery against Infections

    Pharmaceutics, Vol. 15, Núm. 7

  4. Burden of disease attributable to risk factors in European countries: a scoping literature review

    Archives of Public Health, Vol. 81, Núm. 1

  5. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices

    Epidemiology and Infection

  6. Characterization of Leishmania Parasites Isolated from Naturally Infected Mammals

    Animals, Vol. 13, Núm. 13

  7. División celular y muerte programada

    Biología celular biomédica (Elsevier), pp. 354-374

  8. Mixed micelles and gels of a hydrophilic poloxamine (Tetronic 1307) and miltefosine: Structural characterization by small-angle neutron scattering and in vitro evaluation for the treatment of leishmaniasis

    Journal of Molecular Liquids, Vol. 379

  9. The most prominent modulated Annexins during parasitic infections

    Acta Tropica, Vol. 243

2022

  1. Correction to: A rapid and low‑cost protocol for the detection of B.1.1.7 lineage of SARS‑CoV‑2 by using SYBR Green‑based RT‑qPCR (Molecular Biology Reports, (2021), 48, 11, (7243-7249), 10.1007/s11033-021-06717-y)

    Molecular Biology Reports

  2. Host cell proteins modulated upon Toxoplasma infection identified using proteomic approaches: a molecular rationale

    Parasitology Research, Vol. 121, Núm. 7, pp. 1853-1865

  3. Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

    Biomolecules, Vol. 12, Núm. 2

  4. Mining the Proteome of Toxoplasma Parasites Seeking Vaccine and Diagnostic Candidates

    Animals, Vol. 12, Núm. 9

  5. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

  6. Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential

    Parasitology Research, Vol. 121, Núm. 1, pp. 49-62

  7. The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  8. The Defensive Interactions of Prominent Infectious Protozoan Parasites: The Host’s Complement System

    Biomolecules, Vol. 12, Núm. 11